ArticleTherapeutic advances in medical oncology2025
Menopause-related side effects in HR+ early breast cancer: insights from clinical practice.
Article in Therapeutic advances in medical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Ovarian function suppression (OFS) and premature menopause lead to side effects that significantly worsen the quality of life for young women with hormone receptor-positive early breast cancer (HR+ eBC). Objectives: We retrospectively analyzed the most common side effects of OFS and endocrine therapy (ET) in young women with HR+ eBC. Design: This analysis was designed as a combined cohort study according to STROBE criteria. Methods: We retrospectively identified 118 patients (pts); after excluding pts with luteinizing hormone-releasing hormone analogs given for fertility preservation only and pts with permanent castration (surgical or by irradiation), 100 pts were included in the final analysis. We analyzed side effects that were represented by more than 10% of patients at any predefined time points. We looked at the frequency and dynamics of these side effects over time-baseline, 6th, 12th, 18th, 24th, 30th, and 36th month according to three categories-the entire population, according to age (younger and older than 40 years), and according to previous treatment (chemotherapy or not). Results: The most commonly reported side effects among the entire patient group were vasomotor symptoms, particularly hot flashes and night sweats. Sleep disturbances and anxiety were also reported, though less frequently. The most significant worsening of vasomotor symptoms occurred within the first 6 months. Women under 40 years of age reported night sweats and sleep disturbances more often than women aged 40 and older at all time points, with statistically significant differences observed at 30 months for both symptoms and at 12 months for night sweats alone. Among patients who did not receive CT, hot flashes were frequently reported; however, only night sweats showed a statistically significant difference at 6 months compared to the group that did receive CT. No significant differences were found in the frequency of sleep disturbances or anxiety between these groups. Conclusion: Young women with HR+ eBC undergoing OFS plus ET commonly report side effects in clinical practice. The most frequently reported symptoms are hot flashes, night sweats, sleep disturbances, and anxiety. All symptoms were more pronounced at the 30-month follow-up compared to baseline.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.